Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2019

Felix J F Herth; Dirk-Jan Slebos; Gerard J Criner; Arschang Valipour; Frank Sciurba; Pallav L Shah

doi:10.1159/000496122

Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2019

Felix J F Herth, Dirk-Jan Slebos, Gerard J Criner, Arschang Valipour, Frank Sciurba, Pallav L Shah

Groningen Research Institute for Asthma and COPD (GRIAC)

Research output: Contribution to journal › Article › Academic › peer-review

102 Citations (Scopus)

325 Downloads (Pure)

Abstract

Endoscopic lung volume reduction (ELVR) therapies are gaining prominence as a treatment option with guideline recommendations by COPD GOLD and NICE and the recent FDA approval for endobronchial valves. The transition from an experiment-based therapy only to clinical care comes with new challenges. A significant volume of evidence-based data has been published; all data demonstrate consistent improvements in several aspects of patient outcomes. Patients suffering from severe air trapping and thoracic hyperinflation seem to benefit the most from ELVR. In addition to lung function, baseline assessment should ideally include cardiopulmonary exercise testing, high-resolution computer tomography scan, perfusion scintigraphy, and echocardiography. This expert ELVR statement updates best practice recommendations from 2017 regarding patient selection and utilization of these various techniques for treating patients with advanced emphysema.

Original language	English
Pages (from-to)	548-557
Number of pages	10
Journal	Respiration
Volume	97
Issue number	6
DOIs	https://doi.org/10.1159/000496122
Publication status	Published - Jun-2019

Access to Document

10.1159/000496122

Endoscopic Lung Volume ReductionFinal publisher's version, 287 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{df4a9f113ff742299d1e9487014e06c4,

title = "Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2019",

abstract = "Endoscopic lung volume reduction (ELVR) therapies are gaining prominence as a treatment option with guideline recommendations by COPD GOLD and NICE and the recent FDA approval for endobronchial valves. The transition from an experiment-based therapy only to clinical care comes with new challenges. A significant volume of evidence-based data has been published; all data demonstrate consistent improvements in several aspects of patient outcomes. Patients suffering from severe air trapping and thoracic hyperinflation seem to benefit the most from ELVR. In addition to lung function, baseline assessment should ideally include cardiopulmonary exercise testing, high-resolution computer tomography scan, perfusion scintigraphy, and echocardiography. This expert ELVR statement updates best practice recommendations from 2017 regarding patient selection and utilization of these various techniques for treating patients with advanced emphysema.",

author = "Herth, {Felix J F} and Dirk-Jan Slebos and Criner, {Gerard J} and Arschang Valipour and Frank Sciurba and Shah, {Pallav L}",

note = "{\textcopyright} 2019 S. Karger AG, Basel.",

year = "2019",

month = jun,

doi = "10.1159/000496122",

language = "English",

volume = "97",

pages = "548--557",

journal = "Respiration",

issn = "0025-7931",

publisher = "KARGER",

number = "6",

}

TY - JOUR

T1 - Endoscopic Lung Volume Reduction

T2 - An Expert Panel Recommendation - Update 2019

AU - Herth, Felix J F

AU - Slebos, Dirk-Jan

AU - Criner, Gerard J

AU - Valipour, Arschang

AU - Sciurba, Frank

AU - Shah, Pallav L

PY - 2019/6

Y1 - 2019/6

N2 - Endoscopic lung volume reduction (ELVR) therapies are gaining prominence as a treatment option with guideline recommendations by COPD GOLD and NICE and the recent FDA approval for endobronchial valves. The transition from an experiment-based therapy only to clinical care comes with new challenges. A significant volume of evidence-based data has been published; all data demonstrate consistent improvements in several aspects of patient outcomes. Patients suffering from severe air trapping and thoracic hyperinflation seem to benefit the most from ELVR. In addition to lung function, baseline assessment should ideally include cardiopulmonary exercise testing, high-resolution computer tomography scan, perfusion scintigraphy, and echocardiography. This expert ELVR statement updates best practice recommendations from 2017 regarding patient selection and utilization of these various techniques for treating patients with advanced emphysema.

AB - Endoscopic lung volume reduction (ELVR) therapies are gaining prominence as a treatment option with guideline recommendations by COPD GOLD and NICE and the recent FDA approval for endobronchial valves. The transition from an experiment-based therapy only to clinical care comes with new challenges. A significant volume of evidence-based data has been published; all data demonstrate consistent improvements in several aspects of patient outcomes. Patients suffering from severe air trapping and thoracic hyperinflation seem to benefit the most from ELVR. In addition to lung function, baseline assessment should ideally include cardiopulmonary exercise testing, high-resolution computer tomography scan, perfusion scintigraphy, and echocardiography. This expert ELVR statement updates best practice recommendations from 2017 regarding patient selection and utilization of these various techniques for treating patients with advanced emphysema.

U2 - 10.1159/000496122

DO - 10.1159/000496122

M3 - Article

C2 - 30836374

SN - 0025-7931

VL - 97

SP - 548

EP - 557

JO - Respiration

JF - Respiration

IS - 6

ER -

Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2019

Abstract

Access to Document

Handle.net

Fingerprint

Cite this